Home » Stocks » Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. (TARS)

Stock Price: $22.00 USD 1.42 (6.90%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $22.01 +0.01 (0.05%) Oct 19, 4:09 PM

Stock Price Chart

Key Info

Market Cap 423.70M
Revenue (ttm) n/a
Net Income (ttm) -7.30M
Shares Out 19.26M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $22.00
Previous Close $20.58
Change ($) 1.42
Change (%) 6.90%
Day's Open 18.30
Day's Range 18.30 - 23.50
Day's Volume 282,150
52-Week Range 15.32 - 23.50

More Stats

Market Cap 423.70M
Enterprise Value 370.54M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 19.26M
Float 7.97M
EPS (basic) n/a
EPS (diluted) -0.38
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -7.30M
Free Cash Flow n/a
Net Cash 53.16M
Net Cash / Share 2.76
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-4.30-1.35
Net Income-4.67-1.32
Shares Outstanding2.361.76
Earnings Per Share-1.98-0.75
Operating Cash Flow-3.67-1.18
Capital Expenditures-0.18-0.01
Free Cash Flow-3.85-1.19
Cash & Equivalents57.972.38
Net Cash / Debt57.972.38
Book Value-6.01-1.35
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Tarsus Pharmaceuticals, Inc.
Country United States
Employees 12
CEO Bobak Azamian

Stock Information

Ticker Symbol TARS
Stock Exchange NASDAQ
Sector Health Technology
Industry Pharmaceuticals: Major
Unique Identifier NASDAQ: TARS
IPO Date October 16, 2020


Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives. Our lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis (“Blephar” is a reference to eyelid and “itis” is a reference to inflammation) is a condition characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes in Demodex blepharitis. The healthy interaction of the eyelid and the surface of the eyeball is crucial to ocular health. Poorly controlled and progressive blepharitis can lead to worsening of corneal damage over time and, in extreme cases, blindness. According to published studies, there are an estimated 20 million patients in the United States who suffer from blepharitis, with approximately 45%, or approximately nine million, of cases caused by Demodex infestation.